Patents by Inventor Aya Keshi

Aya Keshi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11174310
    Abstract: The present invention provides antibodies that show specific reactivity to disulfide-type HMGB1. Furthermore, the present invention provides methods for specifically measuring disulfide-type HMGB1 using the antibodies, and kits or reagents for the measurement. The present invention also provides methods for measuring total HMGB1 using such an antibody and an antibody that binds to both disulfide-type HMGB1 and reduced-type HMGB1 but does not bind to des-HMGB1, and kits or reagents for the measurement.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: November 16, 2021
    Assignee: Fuso Pharmaceutical Industries, Ltd.
    Inventors: Masahiro Asakura, Aya Keshi, Kanako Abe, Nana Sakamoto, Shiho Yamazaki, Hirotsugu Uehara
  • Publication number: 20190375834
    Abstract: The present invention provides antibodies that show specific reactivity to disulfide-type HMGB1. Furthermore, the present invention provides methods for specifically measuring disulfide-type HMGB1 using the antibodies, and kits or reagents for the measurement. The present invention also provides methods for measuring total HMGB1 using such an antibody and an antibody that binds to both disulfide-type HMGB1 and reduced-type HMGB1 but does not bind to des-HMGB1, and kits or reagents for the measurement.
    Type: Application
    Filed: October 19, 2017
    Publication date: December 12, 2019
    Inventors: Masahiro Asakura, Aya Keshi, Kanako Abe, Nana Sakamoto, Shiho Yamazaki, Hirotsugu Uehara
  • Publication number: 20180246121
    Abstract: It was found that when measuring HMGB1 in samples using antibodies that bind to both HMGB2 and HMGB1, the reaction between HMGB2 and HMGB1 antibodies can be suppressed by coexisting HMGB2 absorbents (HMGB2 antibodies and/or HMGB2-derived peptides that inhibit the binding between HMGB2 and HMGB1 antibodies). More specifically, it was revealed that HMGB1 alone in samples can be measured or detected by contacting the samples with HMGB1 antibodies in the presence of HMGB2 absorbents.
    Type: Application
    Filed: August 19, 2016
    Publication date: August 30, 2018
    Applicants: Fuso Pharmaceutical Industries, Ltd., Canon Kabushiki Kaisha
    Inventors: Masahiro Asakura, Aya Keshi, Masaaki Kobayashi
  • Patent number: 9018354
    Abstract: An objective of the present invention is to provide methods of producing human collagen molecules that are easy to isolate and purify and that have a structure substantially equivalent to that of a natural collagen molecule, wherein host cells that are transduced with a collagen gene synthesize large amounts of human collagen protein derived from a gene introduced into a high exogenous gene expression vector. Another objective of the present invention is to provide collagen molecules produced by the production methods. The present inventors discovered that a large amount of human collagen hardly contaminated with host cell-derived collagen could be produced, by selecting from various mammalian cells a host cell that has low collagen expression and introducing a collagen gene construct into a vector capable of high exogenous gene expression.
    Type: Grant
    Filed: March 31, 2006
    Date of Patent: April 28, 2015
    Assignees: Fuso Pharmaceutical Industries, Ltd., Osaka Prefectural Government
    Inventors: Tetsuo Kase, Akio Kimura, Hiroshi Ueyama, Mizuki Nishihara, Yoko Kisaki, Aya Keshi
  • Publication number: 20120172577
    Abstract: An objective of the present invention is to provide methods of producing human collagen molecules that are easy to isolate and purify and that have a structure substantially equivalent to that of a natural collagen molecule, wherein host cells that are transduced with a collagen gene synthesize large amounts of human collagen protein derived from a gene introduced into a high exogenous gene expression vector. Another objective of the present invention is to provide collagen molecules produced by the production methods. The present inventors discovered that a large amount of human collagen hardly contaminated with host cell-derived collagen could be produced, by selecting from various mammalian cells a host cell that has low collagen expression and introducing a collagen gene construct into a vector capable of high exogenous gene expression.
    Type: Application
    Filed: March 31, 2006
    Publication date: July 5, 2012
    Inventors: Tetsuo Kase, Akio Kimura, Hiroshi Kisaki, Yoko Kisaki, Hiroyuki Keshi, Aya Keshi, Hiroshi Ueyama, Mizuki Nishihara
  • Publication number: 20120015400
    Abstract: Disclosed is the novel hCL-K1 polypeptide which offers collectin activity. This polypeptide consists of consecutive 271 amino acids set out in SEQ ID NO: 2 and does not bind to both maltose and N-acetylgalactosamine.
    Type: Application
    Filed: April 15, 2011
    Publication date: January 19, 2012
    Applicants: ASAHIKAWA MEDICAL COLLEGE, FUSO PHARMACEUTICAL INDUSTRIES, LTD.
    Inventors: Nobutaka Wakamiya, Katsuki Otani, Takashi Sakamoto, Yuichiro Kishi, Hiroyuki Keshi, Aya Keshi
  • Publication number: 20090305341
    Abstract: Disclosed is the novel hCL-K1 polypeptide which offer collectin activity. This polypeptide consists of consecutive 271 amino acids set out in SEQ ID NO: 2 and does not bind to both maltose and N-acetylgalactosamine.
    Type: Application
    Filed: April 5, 2007
    Publication date: December 10, 2009
    Applicants: FUSO PHARMACEUTICAL INDUSTRIES, LTD, ASAHIKAWA MEDICAL COLLEGE
    Inventors: Nobutaka Wakamiya, Katsuki Otani, Takashi Sakamoto, Yuichiro Kishi, Hiroyuki Keshi, Aya Keshi